Renal cell carcinoma with central nervous system demyelination caused by nivolumab

INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65‐year‐old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain‐enhanced magnetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oka, Toshiki, Yamamoto, Yoshiyuki, Okuda, Yohei, Asakura, Toshihisa, Hatano, Koji, Nakai, Yasutomo, Nakayama, Masashi, Kakimoto, Ken‐ichi, Sugai, Fuminobu, Nishimura, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784733/
https://www.ncbi.nlm.nih.gov/pubmed/33426497
http://dx.doi.org/10.1002/iju5.12234
_version_ 1783632344635146240
author Oka, Toshiki
Yamamoto, Yoshiyuki
Okuda, Yohei
Asakura, Toshihisa
Hatano, Koji
Nakai, Yasutomo
Nakayama, Masashi
Kakimoto, Ken‐ichi
Sugai, Fuminobu
Nishimura, Kazuo
author_facet Oka, Toshiki
Yamamoto, Yoshiyuki
Okuda, Yohei
Asakura, Toshihisa
Hatano, Koji
Nakai, Yasutomo
Nakayama, Masashi
Kakimoto, Ken‐ichi
Sugai, Fuminobu
Nishimura, Kazuo
author_sort Oka, Toshiki
collection PubMed
description INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65‐year‐old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain‐enhanced magnetic resonance imaging revealed multiple lesions with partial contrast effects in the cerebral white matter. We tentatively diagnosed demyelination caused by nivolumab, and performed steroid pulse therapy twice. After that, his symptoms improved. For the next 2 years, his symptoms did not recur, nor did his cancer progress. CONCLUSION: Demyelination caused by immune checkpoint inhibitors can be fatal and requires early diagnosis and treatment.
format Online
Article
Text
id pubmed-7784733
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77847332021-01-08 Renal cell carcinoma with central nervous system demyelination caused by nivolumab Oka, Toshiki Yamamoto, Yoshiyuki Okuda, Yohei Asakura, Toshihisa Hatano, Koji Nakai, Yasutomo Nakayama, Masashi Kakimoto, Ken‐ichi Sugai, Fuminobu Nishimura, Kazuo IJU Case Rep Case Reports INTRODUCTION: Central nervous system demyelination caused by immune checkpoint inhibitors is a very rare condition. CASE PRESENTATION: A 65‐year‐old man who received nivolumab for renal cell carcinoma developed abnormal behavior, such as disagreeable speech and sudden anger. Brain‐enhanced magnetic resonance imaging revealed multiple lesions with partial contrast effects in the cerebral white matter. We tentatively diagnosed demyelination caused by nivolumab, and performed steroid pulse therapy twice. After that, his symptoms improved. For the next 2 years, his symptoms did not recur, nor did his cancer progress. CONCLUSION: Demyelination caused by immune checkpoint inhibitors can be fatal and requires early diagnosis and treatment. John Wiley and Sons Inc. 2020-10-28 /pmc/articles/PMC7784733/ /pubmed/33426497 http://dx.doi.org/10.1002/iju5.12234 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Oka, Toshiki
Yamamoto, Yoshiyuki
Okuda, Yohei
Asakura, Toshihisa
Hatano, Koji
Nakai, Yasutomo
Nakayama, Masashi
Kakimoto, Ken‐ichi
Sugai, Fuminobu
Nishimura, Kazuo
Renal cell carcinoma with central nervous system demyelination caused by nivolumab
title Renal cell carcinoma with central nervous system demyelination caused by nivolumab
title_full Renal cell carcinoma with central nervous system demyelination caused by nivolumab
title_fullStr Renal cell carcinoma with central nervous system demyelination caused by nivolumab
title_full_unstemmed Renal cell carcinoma with central nervous system demyelination caused by nivolumab
title_short Renal cell carcinoma with central nervous system demyelination caused by nivolumab
title_sort renal cell carcinoma with central nervous system demyelination caused by nivolumab
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784733/
https://www.ncbi.nlm.nih.gov/pubmed/33426497
http://dx.doi.org/10.1002/iju5.12234
work_keys_str_mv AT okatoshiki renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT yamamotoyoshiyuki renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT okudayohei renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT asakuratoshihisa renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT hatanokoji renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT nakaiyasutomo renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT nakayamamasashi renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT kakimotokenichi renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT sugaifuminobu renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab
AT nishimurakazuo renalcellcarcinomawithcentralnervoussystemdemyelinationcausedbynivolumab

Ejemplares similares